{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:01:31Z","timestamp":1757703691824},"reference-count":2,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamacardio.2018.2379","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T15:31:00Z","timestamp":1533742260000},"page":"897","source":"Crossref","is-referenced-by-count":5,"title":["Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific <i>ADCY9<\/i> Genotype"],"prefix":"10.1001","volume":"3","author":[{"given":"Marc A.","family":"Pfeffer","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute Coordinating Center, Universite de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"hle180014r1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","article-title":"ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study.","volume":"3","author":"Nissen","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hle180014r2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2696436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T16:04:27Z","timestamp":1537373067000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.2379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":2,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.2379","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}